Details of the Drug
General Information of Drug (ID: DMCDV1O)
Drug Name |
1-(4-Chloro-phenyl)-2-phenyl-ethane-1,2-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-Chlorobenzil; 22711-23-5; 1-(4-chlorophenyl)-2-phenylethane-1,2-dione; 4-Chlorodibenzoyl; (p-Chlorophenyl)phenylethanedione; QDCKVAZDINMMHO-UHFFFAOYSA-N; 1-(4-Chlorophenyl)-2-phenylethan-1,2-dione; 1-(4-Chlorophenyl)-2-phenyl-1,2-ethanedione; 1,2-Ethanedione,1-(4-chlorophenyl)-2-phenyl-; p-Chlorbenzil; EINECS 245-169-3; ACMC-20amkt; 1-(4-Chloro-phenyl)-2-phenyl-ethane; AC1L3IMU; Benzil-based compound, 15; SCHEMBL912515; CHEMBL192180; CTK4F0011; BDBM22737; DTXSID00177246; 4-Chlorobibenzyl-alpha,beta-dione; MolPort-001-763-274
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 244.67 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||